ArticleMedical immunology (London, England)2006
The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs.
Article in Medical immunology (London, England), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Role of PRDM1 in natural killer cells.Molecular biology reports · 2026Review
- Article
- A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism.Communications medicine · 2024Article
- Distinct transcriptomic and epigenomic modalities underpin human memory T cell subsets and their activation potential.Communications biology · 2023Article
- A high-throughput, 28-day, microfluidic model of gingival tissue inflammation and recovery.Communications biology · 2023Article
- Imaging of Activated T Cells.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- Engineering IL-2 for immunotherapy of autoimmunity and cancer.Nature reviews. Immunology · 2022Review
- PRDM1 decreases sensitivity of human NK cells to IL2-induced cell expansion by directly repressing CD25 (IL2RA).Journal of leukocyte biology · 2021Article
- Suppressive Mechanisms Induced by Tregs in Celiac DiseaseIranian biomedical journal · 2020Review
- Signaling and Function of Interleukin-2 in T Lymphocytes.Annual review of immunology · 2018Review
- Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.Therapeutic advances in neurological disorders · 2017Review
- Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics.Frontiers in immunology · 2013Review
- Insufficient (sub-native) helix content in soluble/solid aggregates of recombinant and engineered forms of IL-2 throws light on how aggregated IL-2 is biologically active.The protein journal · 2012Article
- Dendritic cells control CD4+CD25+ Treg cell suppressor function in vitro through juxtacrine delivery of IL-2.PloS one · 2012Article
- The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses.Cancer management and research · 2012Article
- Foxp3+ Regulatory T-cells and IL-2: The Moirai of T-cell Fates?Frontiers in immunology · 2012Article
- Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases.Immunology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interleukin-2 molecule and receptor were the first of the interleukins to be discovered and characterized at the molecular level. Now after 20 years of effort, two groups have succeeded in determining the structure of IL2 bound to the external domains of the three receptor chains in a quaternary complex. What do we know now that we did not know before this structural information was available, and how do these new data help us to develop new therapies?
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.